Clonal haemopoiesis in myeloid bone marrow disorders/CHIP (ver1)
Research type
Research Study
Full title
A longitudinal, cohort study to understand clonal haemopoiesis and immune modulation in the healthy ageing population and in myeloid neoplasms and bone marrow failure
IRAS ID
253604
Contact name
Ghulam Mufti
Contact email
Sponsor organisation
King’s College London
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
As we all get older, gene changes occur in our blood. Some of these changes may point to an increased risk in some people of heart disease, stroke, diabetes, and cancers including leukaemia (AML). In blood cancers, such as myelodysplastic syndrome (MDS) and AML, gene changes occur that affect the normal function of cells in the blood. The body’s immune system can either help control and remove dysfunctional cells or make these cells more active and harmful which in some cases leads to cancer or other diseases. Since similar gene changes in the blood are also seen in healthy people or in people with non-cancerous blood disorders, we aim to understand the detailed events that indicate higher risk for disease in order to improve diagnosis and treatment for improved patient outcomes.
This study will look at several thousand healthy people who are older than 50 years and those patients with a myeloid neoplasm such as MDS or AML, or bone marrow failure. The study involves taking blood and bone marrow samples from participants and clinical data at enrolment. The patients are followed for 6 monthly visits over 5 years to monitor changes in the blood and update changes to health. The purpose of this study is to find out: (1) how often do these gene changes occur in the blood over time, (2) how changes in the immune system might be linked to these changes in the blood and bone marrow, (3) what do these changes mean for short- and long-term health? (4) what are the effects of different treatments on the immune system and blood cells with these gene changes?
REC name
London - Bloomsbury Research Ethics Committee
REC reference
19/LO/1646
Date of REC Opinion
15 Oct 2019
REC opinion
Favourable Opinion